Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients
Table 3
CMV viremia in CMV sero(+) versus sero(−) patients in the DES and non-DES groups.
DES group ()
Non-DES group ()
value (DES versus non-DES)
CMV sero(+) ()
CMV sero(−) ()
value (sero+ versus −)
CMV sero(+) ()
CMV sero(−) ()
value (sero+ versus −)
In CMV sero(+)
In CMV sero(−)
CMV-PCR > 5.0 copies/PCR
Viremia rate
32.0 ± 4.0
22.1 ± 5.7
0.37
33.4 ± 3.5
43.5 ± 5.5
0.01
0.95
0.03
1st viremia (m post-Tx)
6.0 ± 11.0
4.3 ± 2.8
0.25
9.1 ± 16.7
4.9 ± 5.9
0.02
0.14
0.60
Peak levels (copies/PCR)
237 ± 578
1652 ± 2236
0.06
2951 ± 22399
2407 ± 4370
0.81
0.22
0.42
Duration (m)
0.7 ± 0.6
0.9 ± 0.6
0.22
0.9 ± 1.1
1.6 ± 3.1
0.11
0.15
0.17
CMV-PCR > 30 copies/PCR
Viremia rate
15.5 ± 2.2
20.3 ± 5.5
0.41
22.5 ± 3.3
35.1 ± 5.1
<0.001
0.34
0.09
1st viremia (m post-Tx)
3.5 ± 4.2
4.4 ± 2.8
0.42
8.1 ± 15.2
4.5 ± 5.9
0.09
0.02
0.94
Peak levels (copies/PCR)
423 ± 734
1801 ± 2278
0.09
4549 ± 27703
2919 ± 4658
0.64
0.23
0.28
Duration (m)
0.7 ± 0.5
1.0 ± 0.6
0.16
1.1 ± 1.3
1.8 ± 3.4
0.20
0.02
0.15
CMV-PCR > 50 copies/PCR
Viremia rate
12.7 ± 2.0
18.6 ± 5.4
0.30
18.7 ± 3.3
35.1 ± 5.1
<0.001
0.59
0.05
1st viremia (m post-Tx)
3.1 ± 3.1
4.4 ± 3.0
0.27
9.2 ± 16.7
4.5 ± 5.9
0.06
0.01
0.93
Peak levels (copies/PCR)
496 ± 779
1978 ± 2316
0.09
5718 ± 30980
2919 ± 4658
0.52
0.23
0.38
Duration (m)
0.8 ± 0.5
1.1 ± 0.6
0.15
1.2 ± 1.4
1.8 ± 3.4
0.29
0.03
0.19
The viremia rates (% ± standard error [SE]) at 5 years after transplant (Tx) were estimated by the Kaplan-Meier method and the group differences were assessed by the log-rank test. Results for 1st viremia, peak levels, and duration are mean ± standard deviation (SD). DES: desensitization; post-Tx: posttransplant.
